HALIFAX — Bank of Nova Scotia significantly reduced its holding in U.S. health insurer Humana Inc., selling 308,864 shares during the first quarter and cutting its position by 85.6%, according to a recent filing with the U.S. Securities and Exchange Commission.
Numbers behind the move
After the sale, the bank retained 51,929 shares of Humana. At the close of the reporting period the remaining stake was valued at approximately $9,004,000. The transaction was disclosed in the fund’s most recent Form 13F filing.
| Metric | Value |
|---|---|
| Shares sold | 308,864 |
| Shares remaining | 51,929 |
| Value at quarter end | $9,004,000 |
Market context and Humana's profile
Humana trades on the New York Stock Exchange under the ticker HUM. At the time the data was compiled, the company’s 12‑month trading range spanned a low of $163.11 and a high of $428.88, with recent indicators including a 50‑day moving average near $364.10 and a 200‑day average around $264.93. The insurer reported quarterly results at the end of April that showed earnings per share of $10.31, ahead of analysts’ consensus.
Institutional ownership and wider investor activity
The filing notes that institutional investors hold the vast majority of Humana shares — roughly 92.38%. Other investment managers have also adjusted positions during recent quarters, with a mix of small purchases and new stakes reported by several firms. The bank’s reduction is therefore one of many portfolio moves among large holders.
- Sales by other institutional managers included some incremental buys and new, modest stakes.
- Humana’s market capitalisation and valuation metrics show it remains a large-cap healthcare insurer.
- The bank’s remaining stake equates to a multimillion-dollar holding despite the large disposition.
What this means for Nova Scotia and local investors
Scotiabank — formally Bank of Nova Scotia — is among Canada’s largest banks and retains historical roots in Nova Scotia. When a major homegrown financial institution alters positions in a single U.S. equity, local observers often watch for signals about portfolio rebalancing, risk management or shifts in asset allocation. However, a regulatory filing alone does not explain the rationale behind the sale.
Institutional managers commonly trim or reweight positions for many routine reasons: to lock in gains, to reduce sector concentration, to raise cash for other opportunities, or as part of broader strategy adjustments tied to fund mandates. The filing does not specify which, if any, of those motives apply in this case.
Practical takeaways for readers
For individual investors and Nova Scotia residents who hold bank stock or mutual funds tied to major Canadian banks, the disclosure is a reminder that large institutions actively manage cross‑border holdings. It does not by itself indicate material weakness or strength in either Humana or Bank of Nova Scotia — rather, it documents a substantial reallocation within one reporting period.
Readers seeking to understand the potential market impact can consider these steps:
- Check fund and bank quarterly reports for supplementary commentary or strategy notes.
- Watch subsequent Form 13F filings for further adjustments from the same manager.
- Seek diversified advice before altering personal portfolios; single institutional transactions are one of many data points.
The numerical disclosure adds to the record of how large financial institutions are positioning themselves in the evolving healthcare and insurance space in the wake of recent earnings and market dynamics. For Nova Scotia, the file is another illustration of how decisions made by major banks — even in routine portfolio management — intersect with global capital markets.
Jerome Beals is NEXO RADAR’s Nova Scotia correspondent, covering finance and community impacts across the province.
